CRISPR is revolutionizing medicine by enabling precise DNA edits, treating genetic diseases like sickle cell anemia and ...

Editas Medicine, Inc. (NASDAQ:EDIT) ranks among the best CRISPR stocks to buy. At the European Hematology Association 2025 ...

Sankalp India Foundation's proactive hemoglobinopathy prevention program averts 201 affected births, offering hope for a healthier future.

Beta thalassemia is a blood condition that causes low levels of functional red blood cells, which may sometimes cause mild to severe anemia. Beta thalassemia results from mutations in the HBB gene ...

Genetics plays a crucial role in reproductive medicine, impacting both fertility and the health of offspring. According to ...

Hemoglobinopathies Market The hemoglobinopathies market is advancing rapidly, driven by gene therapy, new drugs, and rising access for trea ...

Vertex Pharmaceuticals’ Casgevy (exagamglogene autotemcel) has continued to show benefits in sickle cell disease (SCD) ...

In the UK, the two most common haemoglobinopathies are sickle cell disease and beta thalassaemia. This article, the first of four in a series on sickle cell disease and beta thalassaemia, outlines ...

Ten-month-old little Azharul should have been toddling around the house by now, but instead, he lies on a hospital bed. Since birth, he has been suffering from beta-thalassemia major. With a cannula ...

CRISPR technology is transforming modern medicine by enabling precise DNA editing to treat genetic disorders, including sickle cell anemia and beta-thalassemia, experts say.

Discover a revolutionary gene therapy method using CRISPR to reactivate dormant genes, offering hope for sickle cell and beta-thalassemia patients.

This strategy opens up new possibilities for treating genetic diseases. The team specifically shows the technology’s potential for the treatment of sickle cell disease and beta-thalassemia, two ...